AVIR vs IOVA vs RDVT

For growth investors, Iovance Biotherapeutics, Inc.

(IOVA) is the stronger pick with 60. 6% revenue growth year-over-year, versus 20. 0% for Red Violet, Inc. (RDVT). Red Violet, Inc. (RDVT) offers the better valuation at 53. 9x trailing P/E (36. 5x forward), making it the more compelling value choice. Analysts rate Iovance Biotherapeutics, Inc. (IOVA) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Red Violet, Inc.

(RDVT) delivered a total return of +155. 9%, compared to -87. 6% for Iovance Biotherapeutics, Inc. (IOVA). Over 10 years, the gap is even starker: RDVT returned +6. 4% versus AVIR's -81. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Atea Pharmaceuticals, Inc.

(AVIR) is the lower-risk stock at 1. 05β versus Iovance Biotherapeutics, Inc. 's 2. 01β — meaning IOVA is approximately 91% more volatile than AVIR relative to the S&P 500. On balance sheet safety, Atea Pharmaceuticals, Inc. (AVIR) carries a lower debt/equity ratio of 0% versus 7% for Iovance Biotherapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Iovance Biotherapeutics, Inc.

(IOVA) is pulling ahead at 60. 6% versus 20. 0% for Red Violet, Inc. (RDVT). On earnings-per-share growth, the picture is similar: Red Violet, Inc. grew EPS 82. 0% year-over-year, compared to 3. 0% for Atea Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Red Violet, Inc.

(RDVT) is the more profitable company, earning 14. 6% net margin versus -148. 4% for Iovance Biotherapeutics, Inc. — meaning it keeps 14. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RDVT leads at 14. 6% versus -153. 1% for IOVA. At the gross margin level — before operating expenses — IOVA leads at 97. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for AVIR: 80.

5% to $10. 00.

In this comparison, RDVT (0.

6% yield) pays a dividend. AVIR, IOVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Red Violet, Inc.

(RDVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 17), 0. 6% yield). Iovance Biotherapeutics, Inc. (IOVA) carries a higher beta of 2. 01 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RDVT: +6. 4%, IOVA: -34. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (AVIR (Healthcare) and IOVA (Healthcare) and RDVT (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: AVIR is a small-cap quality compounder stock; IOVA is a small-cap high-growth stock; RDVT is a small-cap high-growth stock. RDVT pays a dividend while AVIR, IOVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.